- PROFESSOR Psychiatry
Psychiatry, American Board of Psychiatry and Neurology
MD, Albert Einstein College of Medicine
Bronx Municipal Hospital Center
Fellowship, Inpatient Psych
New York Hospital
At a recent meeting of the American Psychoanalytic Association, Dr. Harold Koenigsberg presented new findings about patients with borderline personality disorder (BPD) and the distinct neurological differences between them and healthy individuals. Learn more about this research in Inside Mount Sinai.
Harold W. Koenigsberg, M.D., is Professor of Psychiatry at Mount Sinai School of Medicine. He has had a longstanding research and clinical interest in borderline personality disorder (BPD), is coauthor of two books on the treatment of borderline personality disorder, and has published widely on the neurobiology, phenomenology and treatment of the disorder. He is currently studying the emotional instability characteristic of borderline personality disorder. To better understand the neurobiology of emotional instability, he is using functional magnetic resonance imaging (fMRI) methods to identify brain networks activated as borderline patients process emotional and social stimuli. Dr. Koenigsberg is carrying out this work as principal investigator of a National Institute of Mental Health (NIMH) RO1 grant. He is also studying the role of second messenger systems in emotional instability in BPD. A principal area of his interest is in the interaction between the neurobiologic and psychosocial components of the personality disorders. In addition, Dr. Koenigsberg is principal investigator of an NIMH-funded RO1 neuroimaging study of cognitive processing in schizotypal personality disorders and in schizophrenia.
Financial & Billing Information
Please direct any detailed billing or financial inquires to the Mount Sinai Psychiatry billing customer service number at 212-659-8752.
Koenigsberg HW, Fan J, Ochsner KN, Liu X, Guise KG, Pizzarello S, Dorantes C, Guerreri S, Tecuta L, Goodman M, New A, Siever LJ. Neural correlates of the use of psychological distancing to regulate responses to negative social cues: a study of patients with borderline personality disorder. Biological psychiatry 2009 Nov; 66(9).
Koenigsberg HW, Siever LJ, Lee H, Pizzarello S, New AS, Goodman M, Cheng H, Flory J, Prohovnik I. Neural correlates of emotion processing in borderline personality disorder. Psychiatry research 2009 Jun; 172(3).
Koenigsberg HW. Affective instability: toward an integration of neuroscience and psychological perspectives. Journal of personality disorders 2010 Feb; 24(1).
Koenigsberg HW, Siever LJ. Borderline personality disorder . In: New encyclopedia of neuroscience, Squire L, Albright T, Bloom F,Gage F, & Spitzer N (Eds). Elsevier;.
Koenigsberg HW, Woo-Ming AM, Siever LJ, Nathan PR, Gorman JM (Eds). Psychopharmacological treatment of personality disorders. In: A guide to treatments that work, 3rd edition. New York: 2007, Oxford University Press;.
Koenigsberg HW, Harvey PD, Mitropoulou V, Schmeidler J, New AS, Goodman M, Silverman J, Serby M, Schopick F, Siever LJ. Characterizing affective instability in borderline personality disorder. Am J Psychiatry 2002; 159: 784-88.
Koenigsberg HW, Kernberg OF, Stone MH, Appelbaum AH, Yeomans FE, Diamond D. Borderline patients: extending the limits of treatability. New York: 2000, Basic Books; 2000.
Koenigsberg HW, Buchsbaum MS, Buchsbaum BR, Schneiderman JS, Tang CY, New A, Goodman M, Siever LJ. Functional MRI of visuospatial working memory in schizotypal personality disorder: a region-of-interest analysis. Psychol Med 2005 Jul; 35(7): 1019-1030.
Koenigsberg HW, Reynolds D, Goodman M, New AS, Mitropoulou V, Trestman R, Silverman J, Siever LJ. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 2003; 64: 628-34.
Koenigsberg HW, Teicher MH, Mitropoulou V, Navalta C, New AS, Trestman R, Seiver LJ. 24-Hour monitoring of plasma norepinephrine, MHPG, cortisol, growth. J Psychiatr Res 2004; 38: 503-11.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Koenigsberg did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.
Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.
Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.
1100 Park Avenue, Suite 1B
New York, NY 10029
- Personal Check